Artelo biosciences announces research collaboration with trinity college dublin to investigate art27.13 for the treatment of cancer cachexia

La jolla, calif., feb. 02, 2021 (globe newswire) -- artelo biosciences, inc.  (nasdaq:  artl ) today embarks on a collaboration with researchers from trinity college dublin to investigate pre-clinical models of human cancer cachexia, a wasting syndrome that affects up to 80% of all cancer patients and is believed to hasten death in this population.
ARTL Ratings Summary
ARTL Quant Ranking